HIV Updates 2018 – Evaluating New Therapies

HIV Updates 2018 – Evaluating New Therapies

On-Demand Webcast

Ethel Weld, MD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mona Chitre, PharmD
Chief Pharmacy Officer & Vice President Clinical Analytics, Strategy & Innovation
Excellus BlueCross BlueShield
Rochester, New York

Intended Learners

This target audience for this initiative includes managed care pharmacists, medical directors, and other formulary decision-makers involved in the treatment decision-making process for patients with HIV.

Learning Objectives

After completing this activity, participants should be able to:

  • Recognize populations to be screened based on current USPSTF guidelines
  • Compare newly approved medications to their older counterparts
  • Discuss therapies not yet approved but in late-phase development
  • Identify existing and in-development HIV therapies that will likely be incorporated into HIV treatment guidelines in advance of final FDA labeling
Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring webcast.

Release date: August 31, 2018
Expiration date: August 31, 2019
Estimated time to complete: 1 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and DKB Med. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1 contact hour.

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

Planning Committee

The planning committee comprises Mona Chitre; PharmD; Kyle R. Copeland, PharmD; Susie Seaman, NP; Ethel Weld, MD; Dean Beals, Rachel Deerr, Stan Pogroszewski, DKBmed; and Jennifer Ilcyn, Michael Kearney, Randy Robbin, Margie Stefan, Susan Yarbrough, NACCME.

Independent Clinical Reviewer: Kyle R. Copeland, PharmD, Clinical Specialist Pharmacist, Parkwest Medical Center, Assistant Professor, University of Tennessee College of Pharmacy, Knoxville, Tennessee

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California


According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Ms. Seaman: Advisory Board—Mölnlycke

Dr. Weld: Research—Viiv/GSK

Dr. Chitre and Dr. Copeland have disclosed no relevant financial relationships with any commercial interests.

Mr. Beals, Ms. Deerr, Ms. Ilcyn, Mr. Kearney, Mr. Pogroszewski, Mr. Robbin, Ms. Stefan, and Ms. Yarbrough  have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed that no off-label/unapproved uses of drugs and/or devises will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by an educational grant from Gilead Sciences, Inc.